Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
Date:4/30/2008

.7 million decrease primarily resulted from cost savings derived from our completed strategic restructuring and associated termination of prior development programs, partially offset by an increase in development costs for ANA773 and ANA598 in the first quarter of 2008 compared to the first quarter of 2007.

General and administrative expenses remained relatively consistent at approximately $2.1 million for the first quarter of both 2008 and 2007.

Operating expenses were $8.1 million for the first quarter of 2008, compared to $8.8 million for the first quarter of 2007. Included as a component of Anadys' operating expenses were non-cash, share-based expenses of $0.7 million and $1.1 million for the first quarter of 2008 and 2007, respectively.

The net loss was $7.4 million for the first quarter of 2008, compared to a net loss of $6.7 million for the first quarter of 2007. Basic and diluted net loss per common share was $0.26 in the first quarter of 2008 compared to $0.23 in the first quarter of 2007. Non-cash share-based expense resulted in a $0.02 and $0.04 decrease in basic and diluted net loss per share for the three months ended March 31, 2008 and 2007, respectively.

Recent Development Program Highlights

-- Completion of Preclinical Activities and IND filing for ANA598. In the

first quarter, Anadys completed preclinical activities required to

advance ANA598 into clinical studies. Subsequent to the close of the

quarter, Anadys submitted an Investigational New Drug (IND) application

to the U.S. Food and Drug Administration (FDA). Pending allowance of

the IND by the FDA, Anadys expects to commence a Phase I single,

ascending-dose clinical trial in healthy volunteers in the second

quarter of 2008 to assess the safety and pharmacokinetics of ANA598.

Following the healthy volunteer study, Anadys plans to initiate a

short-term Phase Ib study of ANA
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
3. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
11. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 BioTech ... developments, patents and results of studies and trials.  Companies ... and Company (NYSE: LLY ), Gilead Sciences ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ... in developing prodrug therapeutics for the treatment of cancer, ...
(Date:9/19/2014)... Massachusetts , September 19, 2014 ... the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... of science and medical research in the field of ... Merck KGaA, Darmstadt, Germany , today ... Innovation (GGI) for 2014. The awards were announced during ...
(Date:9/18/2014)... 18, 2014 About POCT ... outside a clinical laboratory. It helps in making ... treatments and medication. POCT is gaining popularity due ... diseases such as diabetes, heart disease, and obesity. ... are standardized to minimize errors during the diagnosis ...
(Date:9/18/2014)... Ireland , September 18, 2014 ... and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has ... "Biocompatible Materials - Global Strategic Business ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes ... in US$ Million by the following ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... Sept. 27, 2011 Verenium Corporation (Nasdaq: ... commercializing high-performance enzymes, today announced that it retired its ... of $34.9 million in principal amount of unsecured 5.5% ... approximately $1.1 million in principal amount of its 9% ...
... nanowires may be coming to a little screen near you. ... the costs of displaying information on cell phones, e-readers and ... and improved solar cells, according to new research. Duke ... technique to organize copper atoms in water to form long, ...
... -- Two professors from the University of California, Riverside,s ... study a new approach that could allow the electronics ... in the next generation of computers. Alexander Balandin, ... materials science and engineering program, and Roger Lake, a ...
Cached Biology Technology:Verenium Announces Debt Repurchase 2Verenium Announces Debt Repurchase 3Copper film could lower touch screen, led and solar cell costs 2Bold approach could change electronics industry 2Bold approach could change electronics industry 3
(Date:9/18/2014)... that when people are too stressed they are often ... Brain Mind Institute (BMI) at EPFL have just highlighted ... chronic stress and the loss of social skills and ... a synaptic regulatory molecule in the brain. This was ... . , Carmen Sandi,s team went to look ...
(Date:9/17/2014)... to reproductive technologies, the justice and well-being of ... to identify key issues, articulate their values and ... most defensible ways forward. But what are the ... The Hastings Center and the Presidential Commission for ... to publish a series of essays to highlight ...
(Date:9/17/2014)... 17, 2014) A rare genetic disorder known as Jacobsen ... recent joint investigation by researchers at San Diego State ... addition to suggesting better treatment options for people with ... the genetic underpinnings of autism., Jacobsen syndrome affects approximately ... of Health. It occurs in a person when there ...
Breaking Biology News(10 mins):How stress tears us apart 2Why bioethics literacy matters 2Why bioethics literacy matters 3A link between Jacobsen syndrome and autism 2
... While testing a new drug designed to treat chronic ... could identify which patients would receive maximum benefit from ... the online edition of Blood , a weekly ... Chronic lymphocytic leukemia (CLL), a cancer of ...
... three types of cells derived from human embryonic stem cells ... but are much more developmentally immature than previously thought when ... tissue. The researchers, from the Eli and Edythe Broad ... found that the progeny of the human embryonic stem cells ...
... its kind, researchers have used tools of paleontology to gain ... have shown that during the evolution of these compounds nature ... to synthesise forms, giving pointers that will help in the ... record has allowed the study of the evolution of the ...
Cached Biology News:Cells derived from pluripotent stem cells are developmentally immature 2Cells derived from pluripotent stem cells are developmentally immature 3Nature reaches for the high-hanging fruit 2